🟢 Gilead Sciences, Inc. is trading 2.3% up today after FDA accepts sNDA for once-weekly HIV prevention drug

Gilead Sciences, Inc. is trading 2.3% up now at $47,700.00 after U.S. regulators advanced a key HIV prevention program.

• The FDA has accepted the supplemental New Drug Application (sNDA) for once-weekly oral Yeztugo (lenacapavir) 300-mg tablets as a potential pre-exposure prophylaxis (PrEP) option for HIV prevention.
• This development follows the existing U.S. approval of twice-yearly injectable Yeztugo for HIV-1 PrEP and significantly bolsters the company's HIV prevention franchise.